Last reviewed · How we verify
ILY101
At a glance
| Generic name | ILY101 |
|---|---|
| Sponsor | Ilypsa |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis
- Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease
- Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
- A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis (PHASE3)
- Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis (PHASE3)
- A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis (PHASE3)
- Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ILY101 CI brief — competitive landscape report
- ILY101 updates RSS · CI watch RSS
- Ilypsa portfolio CI